Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen, Pfizer Pen Four-Year PGx Partnership; Deal Covers IP Rights, Research Payments

NEW YORK, Dec. 28 (GenomeWeb News) - Perlegen Sciences and Pfizer have penned a four-year alliance to study whole genomes in an attempt to identity genes linked to undisclosed diseases and drug response, the companies said today.


The announcement, which comes one day after Perlegen disclosed Pfizer bought a 12-percent stake in it for $50 million, calls for researchers from both companies to conduct whole genome studies involving DNA samples from clinical trials. Perlegen will genotype the samples using Affy arrays.

Additional terms of the agreement between Perlegen and Pfizer call for the firms to share "certain" intellectual property rights that could result from the collaboration. Pfizer will provide research payments to Perlegen.

Pfizer and Perlegen originally allied in December 2002 in order to study DNA samples in areas such as metabolic syndrome and drug response in patients with Major Depression Disorder.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.